ENZYMOTEC AND IL DONG TO COLLABORATE ON CVD TREATMENT

Israeli biotech company Enzymotec and Korean pharmaceuticals manufacturer Il Dong have signed an agreement to launch a treatment for cardiovascular disease (CVD) in the Korean market.

The new product, CardiaBeat, based on Enzymotec's clinical trials, enhances the impact of phytosterols and omega-3 fatty acids for reducing the risk for cardiovascular disease. Enzymotec and Il Dong intend to develop additional products for the Korean market, focusing on cardiovascular solutions.